Back
Meningioma.
Journal article

Meningioma.

  • Fathi AR Department of Neurosurgery, Cantonal Hospital, 5001, Aarau, Switzerland. Ali-Reza.Fathi@ksa.ch
  • Roelcke U
  • 2013-03-07
Published in:
  • Current neurology and neuroscience reports. - 2013
Antineoplastic Agents
Cranial Irradiation
Diagnostic Imaging
Endoscopy
Humans
Meningeal Neoplasms
Meningioma
Microsurgery
Molecular Targeted Therapy
Neoplasm Recurrence, Local
Neuronavigation
Prognosis
Receptors, Somatostatin
Somatostatin
English Meningiomas represent the most common primary brain tumor and comprise 3 World Health Organization (WHO) grades, the most frequent being WHO grade I (90%). Surgery is mandatory to establish the diagnosis and to remove the tumor; however, complete resection can be achieved in only <50% of patients. Depending on the extent of resection, tumor location and the WHO grade radiation therapy can be applied. The issue of systemic treatment such as chemotherapy or targeted therapy (eg, somatostatin receptors, antiangiogenic agents) is yet not solved, particularly as current data are derived from small uncontrolled series in patients with long-standing disease and after several pretreatments. A more thorough understanding of molecular genetics, signaling pathways and prognostic factors in meningiomas should lead to the design of studies which stratify according to these factors. These studies have to be conducted in newly diagnosed patients after incomplete resection and in tumors of WHO grade II and III.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/186683
Statistics
Document views: 11 File downloads: